Skip to main content
LEAP THERAPEUTICS, INC. logo

LEAP THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LPTX ISIN · US52187K2006 LEI · 549300T31SMMJ2DDLI13 US Manufacturing
Open in API
Filings indexed 584 across all filing types
Latest filing 2016-11-22 Merger & Acquisition
Country US United States of America
Listing US LPTX

About LEAP THERAPEUTICS, INC.

https://www.leaptx.com/

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer. Its most advanced clinical candidate, DKN-01 (sirexatamab), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. The company's pipeline also includes FL-301, a monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancer, and FL-501, a preclinical antibody targeting the growth and differentiation factor 15 (GDF-15) protein.

Recent filings

Filing Released Lang Actions
S-4/A
Merger & Acquisition Classification · 100% confidence The document is an Amendment No. 3 to Form S-4 Registration Statement filed with the SEC, related to a proposed merger between Leap Therapeutics, Inc. and Macrocure Ltd. It includes detailed information about the merger agreement, share exchange ratios, shareholder meeting details, and regulatory compliance. Form S-4 is a registration statement used for securities issued in business combinations such as mergers. The content is consistent with merger-related filings, specifically registration statements for securities issued in connection with mergers. This is not a proxy statement, earnings release, or annual report. It is a detailed regulatory filing related to a merger transaction, which fits the category of Merger & Acquisition filings (MA). The document length and detail confirm it is the filing itself, not just an announcement or summary.
2016-11-22 English
Regulatory Filings 2016
Regulatory Filings
2016-11-22 English
Regulatory Filings 2016
Regulatory Filings Classification · 100% confidence The document is a letter from Leap Therapeutics, Inc. to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-4. It references Rule 461 of the Securities Act of 1933 and discusses procedural acknowledgments related to the filing's effectiveness. The document is short (3008 characters) and is a correspondence related to a regulatory filing, not the filing itself. It does not contain financial data or detailed report content but is an administrative request regarding a registration statement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and filings that do not fit other specific categories.
2016-11-21 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter from Leap Therapeutics, Inc. responding to comments from the SEC staff regarding an Amendment No. 1 to a Registration Statement on Form S-4. The content includes detailed responses to SEC comments about merger-related disclosures, pro forma financial statements, and other merger-related information. The Form S-4 is a registration statement used in connection with mergers and acquisitions to register securities to be issued in the transaction. The document is not a full report like an Annual Report or Quarterly Report, nor is it an earnings release or proxy statement. It is a regulatory filing responding to SEC comments on a merger registration statement. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a compliance document filed with the SEC that does not fit other specific categories such as M&A Activity or Merger & Acquisition filings which typically include the actual merger documents or tender offers, not comment responses.
2016-11-16 English
S-4/A
M&A Activity Classification · 95% confidence The document is an Amendment No. 2 to Form S-4 Registration Statement filed with the SEC, related to a proposed merger between Leap Therapeutics, Inc. and Macrocure Ltd. It includes detailed information about the merger agreement, share exchange ratios, shareholder meeting details, and regulatory compliance. Form S-4 is a registration statement used for securities issued in business combinations such as mergers and acquisitions. The content focuses on merger terms, shareholder approvals, and securities issuance, which aligns with filings related to M&A activity. The document is not a proxy statement, earnings release, or annual report, but a registration statement for a merger transaction. Therefore, the appropriate classification is M&A Activity (Code: TAR). The document length and detail support a high confidence level.
2016-11-16 English
Regulatory Filings 2016
Regulatory Filings
2016-11-15 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.